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MRI is widely used in the assessment of acute ischemic stroke. In particular, it identifies
the mismatch between hypoperfused and the permanently damaged tissue, the PWI-DWI
mismatch volume. It is used to help triage patients into active or supportive treatment path-
ways. COMBAT Stroke is an automated software tool for estimating the mismatch volume
and ratio based on MRI. Herein, we validate the decision made by the software with actual
clinical decision rendered. Furthermore, we evaluate the association between treatment
decisions (both automated and actual) and outcomes. COMBAT Stroke was used to deter-
mine PWI-DWI mismatch volume and ratio in 228 patients from two European multi-center
stroke databases. We performed confusion matrix analysis to summarize the agreement
between the automated selection and the clinical decision. Finally, we evaluated the clini-
cal and imaging outcomes of the patients in the four entries of the confusion matrix (true
positive, true negative, false negative, and false positive). About 186 of 228 patients with
acute stroke underwent thrombolytic treatment, with the remaining 42 receiving support-
ive treatment only. Selection based on radiographic criteria using COMBAT Stroke classified
142 patients as potential candidates for thrombolytic treatment and 86 for supportive treat-
ment; 60% sensitivity and 29% specificity. The patients deemed eligible for thrombolytic
treatment by COMBAT Stroke demonstrated significantly higher rates of compromised
tissue salvage, less neurological deficit, and were more likely to experience thrombus dis-
solving and reestablishment of normal blood flow at 24 h follow-up compared to those who
were treated without substantial PWI-DWI mismatch.These results provide evidence that
COMBAT Stroke, in addition to clinical assessment, may offer an optimal framework for a
fast, efficient, and standardized clinical support tool to select patients for thrombolysis in
acute ischemic stroke.
Keywords: stroke, brain edema, magnetic resonance imaging, brain ischemia, decision-support systems, clinical,
thrombolytic therapy
INTRODUCTION
Neuroimaging is valuable to identify acute ischemic stroke patients
that may benefit from thrombolysis (1, 2). Magnetic resonance
based diffusion- and perfusion-weighted imaging (DWI and PWI)
are widely utilized modalities in clinical practice that aid in
treatment selection (3). While DWI hyper-intense regions typ-
ically indicate cytotoxic edema as a surrogate for permanent
tissue injury, delayed PWI regions correspond to tissue with
compromised hemodynamics (4, 5).
The ischemic penumbra is defined as tissue that is hypoper-
fused to such an extent that focal neurological symptoms arise, but
where neurological function can be restored and tissue survival is
ensured by early reperfusion.
Current PWI techniques are not able to distinguish between
critically hypoperfused tissue and benign oligemia. This short-
coming potentially overestimates the actual mismatch volume and
is especially noticeable with small lesions (6). Additionally, hyper-
intense areas on diffusion-weighted images have shown reversal
following thrombolysis (7, 8). Nevertheless, the PWI-DWI mis-
match is recognized as surrogate for risk at tissue that may be viable
if perfusion is restored timely (4, 9, 10). Accordingly, the volume
of the mismatch and the ratio between the volume of mismatch
and volume of permanent injured tissue (PWI-DWI mismatch
ratio) are two practical markers that are used to help triage stroke
patients into interventional or supportive treatment pathways. For
example, when considered along with other parameters, it has been
shown that patients with a mismatch volume>10 mL and a PWI-
DWI mismatch ratio>1.2 have greater benefit from thrombolysis
compared to those without a significant mismatch (11–13). The
time and expertise required to perform these calculations, along
with inter-observer variability are potential factors that may limit
their utilization and efficacy. To overcome these factors, automated
computer-based algorithms for the determination of PWI-DWI
mismatch have been developed (14). The overall aim of this study
was to compare the agreement and outcomes between a solely
automated computer-based patient triage algorithm and the actual
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clinical decision made for thrombolysis. Herein, we tested whether
the treatment decisions of an automated patient selection software
tool “Computer-Based Decision-Support System for Thromboly-
sis in Stroke” (COMBAT Stroke), were associated with 24 h clinical
and imaging outcomes.
MATERIALS AND METHODS
PATIENTS AND DATA ACQUISITION
Following approval from national and regional ethics commit-
tees, patients with acute ischemic stroke were identified from
the European I-Know consortium (2006–2009) and the Remote
Ischemic Perconditioning Study (RIPS, 2009-2011) (15, 16). Clin-
ical information available in the databases includes gender, age,
time from symptom onset to treatment initiation, immediate and
24 h and 3 month follow-up National Institutes of Health Stroke
Scale (NIHSS) score, lesion laterality, stroke etiology subtype,
treatment (i.e., intravenous recombinant tissue plasminogen acti-
vator (rt-PA), or supportive treatment), admission blood pressure,
presence of intracranial hemorrhage, home medications, platelet
count, and MR angiography-based recanalization status at 24 h.
Only adult patients (age >18) with acute ischemic stroke in the
anterior circulation territory were included. Patients with ischemic
strokes of the vertebrobasilar circulation were excluded.
Standard dynamic susceptibility contrast MRI was performed
on various scanner types at different field strengths (GE Signa
Excite 1.5T, GE Signa Excite 3T, GE Signa HDx 1.5T, GE Signa
Horizon 1.5T, Siemens TrioTim 3T, Siemens Avanto 1.5T, Siemens
Sonata 1.5T, Philips Gyroscan NT 1.5T, Phillips Achieva 1.5T, and
Philips Intera 1.5T). The PWI sequence (TE 30/50 ms for 3 and
1.5 Tesla field strength, TR 1500 ms, FOV 24 cm, matrix 128× 128,
slice thickness 5 mm) was obtained during intravenous injection
of Gadolinium based contrast (0.1 mmol/kg) at a rate of 5 mL/s
followed by 30 mL of physiological saline at the same injection
rate. Echo-planar DWI was obtained at b-value= 0 s/mm2 and
b-value= 1.000 s/mm2. DWI images were automatically linear co-
registered and re-sliced to acute PWI space using SPM8 (Wellcome
Trust Centre for Neuroimaging, UCL, UK).
CLINICAL PRACTICE
Patients form highly specialized stroke centers from Denmark,
Germany, United Kingdom, France, and Spain were included in
this study. The local rt-PA practices follow the general recommen-
dation from American Heart Association, where patients older
than 18 years with no imaging or clinical evidence for hemorrhage
who have significant neurological deficit are eligible for treatment
within 4.5 h of symptom onset. All centers routinely perform DWI
and PWI in clinical practice and use the mismatch information as
well as clinical information in treatment decision-making.
AUTOMATIC MISMATCH ESTIMATION
COMBAT Stroke generates and applies a whole-brain mask to
acute images to exclude non-brain structures, e.g., eyes, cere-
brospinal fluid etc. Next, the software determines the lesion later-
ality by analyzing the acute apparent diffusion coefficient map
(ADC) and the time-to-peak of the tissue curve map (TTP).
The lesion laterality is used to compute a normal tissue refer-
ence and subsequently the algorithm outlines the initially injured
tissue on DWI. Similarly, the algorithm automatically outlines the
hypoperfused lesion on TTP map, and the mismatch is defined as
the part of the hypoperfused lesion that is not contained in the
co-registered DWI lesion. We automatically estimated the PWI-
DWI mismatch ratio and mismatch volume for all patients in the
cohort using COMBAT Stroke.
MANUAL MISMATCH OUTLINING
Comparing automated delineations of the mismatch to those
determined manually by a single expert has the potential to intro-
duce bias, therefore we used four expert raters (neuroradiologists)
with extensive clinical experience in stroke diagnosis. The raters
manually outlined the hypoperfused lesion on TTP maps and the
lesion core on DWI images using in-house developed software.
All raters worked individually and were blinded to each other and
the remainder of the clinical data. Next, an expert rater consensus
mismatch mask was created by summating the ratings (1= lesion;
0= normal) in every image voxel for each of the four expert raters.
We utilized a cutoff summative score of 3 to create the mask to
establish a consensus, consistent with previously described meth-
ods (14). The stroke community has been discussing the optimal
choice of PWI map in stroke management, however no consen-
sus exists. We chose TTP as the PWI modality because of its
perceived superiority in separating normo- and hypoperfused tis-
sue. A recent study demonstrated that TTP performed superior to
deconvolved maps (e.g., MTT and Tmax) in terms of predicting
tissue fate (17).
CONFUSION MATRIX MODELING
Initially, all patients were assessed exclusively on imaging cri-
teria alone: thrombolysis could potentially be administered in
cases were PWI-DWI mismatch ratio >1.2 and mismatch vol-
ume>10 mL. Assessments were made for each patient twice, once
with the use of COMBAT Stroke and again by using the data
generated by the expert neuroradiologists’ consensus. Next, con-
fusion matrices were generated to quantify the performance of (1)
COMBAT Stroke versus actual clinical decision and (2) COMBAT
Stroke versus human measurement. The four entries of the con-
fusion matrix denote true positive (TP, both clinical decision and
COMBAT Stroke agree for thrombolytic therapy), true negative
(TN, both clinical decision and COMBAT Stroke agree for sup-
portive treatment), false positive (FP, COMBAT Stroke supports
thrombolysis, but the patient was treated supportively), and false
negative (FN, COMBAT Stroke advises for supportive treatment,
however the patient was treated with thrombolysis).
Mindful that a multitude of factors are used in the actual clinical
determination of administering thrombolytic treatment, we ana-
lyzed the following presentation variables for the four entries of
the confusion matrix: mismatch volume, NIHSS score, and con-
traindications. The definition of contraindication in this study
was based on the American Heart Association’s Stroke Guidelines
and includes any of the following criteria: systolic blood pres-
sure greater than 185 mmHg, diastolic blood pressure greater than
110 mmHg, evidence of intracranial hemorrhage, use of antico-
agulants, international normalized ratio (INR) greater than 1.7,
and time for symptom onset to treatment greater than 4.5 h, all of
which were available in the database. Subsequently, we analyzed
the clinical outcomes, in terms of mismatch salvage, reduction in
NIHSS score at 24 h, and vessel recanalization determined by MR
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angiography at 24 h, to determine the association between pres-
ence/absence of significant acute mismatch and clinical outcome.
The acute DWI-PWI mismatch was determined as the fraction of
the hypoperfused area, which was not contained in the lesion core
(Figure 1). Infarct evolution at 1 month follow-up was evaluated
on T2 FLAIR for all patients in the cohort. The mismatch salvage
was the portion of the acute mismatch that remained functional at
1 month follow-up. Rank sum-test was conducted to test the dif-
ference in median value of acute decision parameters and clinical
outcomes between the groups.
To examine the relative importance of the presentation vari-
ables (Mismatch volume, NIHSS, and contraindications) in pre-
dicting thrombolytic treatment, we also conducted a classification
and regression tree (CART) analysis. The best spilled of data at
each node was determined by optimization of the Gini’s diversity
index and the analysis was conducted in MATLAB 2010B (The
MathWorks, Inc. Natick, MA, USA).
RESULTS
228 patients (136 males, 92 females) were identified as meeting cri-
teria for analysis from the European I-Know consortium database
and the Remote Ischemic Perconditioning Study. The patient char-
acteristics for the two study populations are shown in Table 1. In
comparison with the I-Know cohort the patients in the RIPS study
had significantly lower neurological deficit at baseline, 24 h, and
3 month follow-up in terms of NIHSS and modified Rankin Score.
No significant difference in the acute mismatch volume between
the I-Know patients [56 mL, 25th and 75th percentile= (5, 133)]
and RIPS patients [36 mL (1, 105)] was observed. 89% of the
patients in the I-Know study were treated actively compared to
100% in the RIPS study. Altogether, 40 patients exceeded the 4.5-h
treatment window, of whom 16 were treated actively. The median
processing time for automatic PWI-DWI mismatch estimation
across all patients was 31 s when processed on an Apple MacBook
Pro, 2.6 GHz Intel Core i7.
CONFUSION MATRIX – COMBAT VERSUS CLINICAL DECISION
186 of 228 patients underwent thrombolytic treatment, with
the remaining 42 patients receiving supportive treatment only
(Figure 2A, columns). Assessment of the cohort based on mis-
match criteria (mismatch> 10 mL and PWI-DWI ratio> 1.2)
alone with COMBAT Stroke classified 142 patients as potential
FIGURE 1 | Schematic illustration of mismatch salvage computation (A,B). The acute lesions are outlined on DWI and TTP (C). Illustrates the concept of
DWI-PWI mismatch (blue region) (D–F). Combining the DWI-PWI mismatch information with the 1-month infarct evolution on T2 FLAIR yields the mismatch
salvage (blue region in F).
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Male 77 (60%) 59 (60%) 0.108
Median age and IQ range, years 70 (60, 77) 69 (61, 76) 0.922
Left hemisphere stroke 74 (57%) 50 (50%) <0.001
IV t-PA 89 (69%) 99 (100%) <0.001
Median time to treatment and IQ
range, min
188 (150, 280) 164 (137, 220) 0.006
Time to treatment>4.5 H 34 (26%) 6 (6%) <0.001
Treated beyond 4.5 H 10 (29%) 6 (100%) 0.002
Median acute NIHSS and IQ
range
11 (6, 16) 6 (4, 10) <0.001
Median 24 h NIHSS and IQ range 4 (1, 10.25) 2 (1, 6) <0.001
Median 3 months NIHSS and IQ
range
2 (0, 6) 0 (0, 2) <0.001
Median 3 months mRS and IQ
range
2 (0, 3) 1 (0, 3) <0.001
Median systolic BP and IQ range
(mmHg)
145 (130, 158) 150 (140, 165) 0.038
Median diastolic blood pressure 83 (72, 90) 85 (79, 90) 0.406
Anticoagulant therapy 22 (17%) 1 (1%) <0.001
Clopidogrel therapy 18 (14%) 6 (6%) 0.027
Median mismatch volume (mL) 56 (5, 133) 36 (1, 105) 0.179
Mismatch volume <10 mL 37 (29%) 33 (33%) 0.086
Mismatch volume <10 and
>100 mL
51 (39%) 38 (38%) 0.031
Mismatch volume >100 mL 41 (32%) 28 (28%) 0.098
STROKE SUB-TYPES
Cardiac source of emboli 58 36 0.046
Large vessel disease with
significant carotid stenosis
22 16 0.140
Large vessel disease, other 12 10 0.174
Small vessel disease (lacunar) 5 24 <0.001
Carotid dissection 6 2 0.172
Other/unusual cause 3 1 0.315
Undetermined 23 10 0.039
Values represented as median with interquartile ranges presented in brackets.
Sample size, where appropriate, is represented as numbers and the percentage
of the cohort is contained in parentheses.
candidates for thrombolytic treatment and 86 for supportive treat-
ment; 60% sensitivity and 29% specificity, 79% positive predictive
value, and 14% negative predictive value (Figure 2A, rows). The
comparison of COMBAT Stroke with treatment decision based
on manually outlined mismatch statistics demonstrated excel-
lent agreement; 93% sensitivity and 95% specificity, 97% positive
predictive value and 87% negative predictive value (Figure 2B).
VOLUMETRIC AGREEMENT
The correlation between PWI-DWI mismatch volumes using
the automatic algorithm and manual outlines performed by
experts was excellent, with Spearman R= 0.89 [CI: (0.86, 0.91)]
(Figure 3). The mean difference in mismatch volume between the
FIGURE 2 | Confusion matrix analysis (A). The confusion matrix
demonstrates the agreement and disagreement between the clinical
decisions actually rendered (columns) and automated patient selection
based on radiographic criteria alone with the COMBAT Stroke software
(rows) (B). The confusion matrix demonstrates the agreement and
disagreement between manual (columns) and automated (rows)
calculations operating under the principle that thrombolysis should
potentially be administered in cases were PWI-DWI mismatch ratio >1.2
and mismatch volume >10 mL.
manual and automatic approach was 8 mL (SD: 35 mL), indicat-
ing an overall underestimation by COMBAT Stroke (Figure 3).
We observed a significant difference in median mismatch volume
in the manual outlines estimated by COMBAT Stroke between
patients scanned on a 1.5T [median mismatch volume= 80 mL
(27, 135), p< 0.01] versus 3T [median mismatch volume= 29 mL
(1, 95)] MRI. Likewise, this difference was apparent in COMBAT
Stroke estimations; 1.5T: median mismatch volume= 62 mL (13,
106), p< 0.01, 3T: median mismatch volume= 15 mL (0, 102).
ACUTE DECISION PARAMETERS
The patients in the TP group (112 patients actually receiv-
ing thrombolytic treatment where COMBAT stroke determined
them to be potential candidates) had significantly higher median
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FIGURE 3 |Volumetric comparisons of mismatch delineations.
On left, x -axis represents the expert consensus mismatch volume and
y -axis represent the mismatch volume estimates by the automatic
approaches. On right, x -axis represents the average mismatch volume
between expert consensus and automatic approaches. The y -axis
represent the difference in mismatch volume between expert
consensus and automatic approaches. The Spearman correlation was
R2 =0.89 [CI: (0.88, 0.91)] for COMBAT Stroke compared with the
manual outlining. The mean difference in volume between manual and
COMBAT Stroke outlining was 8 mL (SD: 35 mL). Solid line indicates
the mean between the two compared methods and dashed lines
indicate mean difference ±2 SD.
mismatch volume [96 mL (48, 144)], compared with TN [12
patients, median= 0 mL (0, 22), p< 0.001], FN [74 patients,
median= 0 mL (0, 3), p< 0.001] and the FP [30 patients,
median= 73.4 mL (28, 109), p= 0.04] (Figure 4A). Addition-
ally, the NIHSS score was significantly higher in the TP group
[median= 11 (7, 16)] compared with TN [median= 6 (4.25,
13.5), p< 0.001], FN [median= 5 (3, 7.5), p< 0.001] and FP
[median= 8 (5, 15), p< 0.001] (Figure 4B). Contraindications
to thrombolysis were present in 83% of the patients in the TN
group and in 73% in the FP group. Among the patients in the
TP and FN groups, contraindications were present in 24 and 23%
of cases, respectively (Figure 4C). A summary of acute decision
parameters statistics and significance levels are given in Table 2 for
TN and FN group.
CLINICAL OUTCOME
The 112 patients in the TP group demonstrated the largest
mismatch salvage [median= 84.8 mL (42, 138)] and signifi-
cantly greater salvage than in the TN [median= 8.2 mL (1, 34),
p< 0.001] and FN groups [median= 1.5 mL (0, 7), p< 0.001].
No significant difference in the volume of salvaged tissue was
observed between the FP group [median= 73.4 mL (44, 109),
p= 0.05] and TP (Figure 4D). The neurological improvement
(assessed by reduction in NIHSS score at 24 h) was significantly
better for the TP group [median= 5 (2, 9)] compared with each
of the other three groups [TN: median= 3 (2, 4), p= 0.03; FN:
median= 1 (−1, 3), p< 0.001; FP: median= 2 (0, 5), p= 0.01]
(Figure 4E). Routine 24 h MR angiography demonstrated recanal-
ization in 42% of the patients in the TP group, 15% of the TN
group, 8% of the FN group, and 10% of the patients in the FP
group (Figure 4F). A summary of 3 month outcomes (mRS and
NIHSS score) are given in Table 2 for TN and FN group.
CART ANALYSIS
According to CART analysis, clinicians based their treatment
decisions on a multitude of factors, but primarily on the pres-
ence/absence of a contraindication (Figure 5). The majority of
the patients who had no contraindications (152 of 228) were
treated with thrombolysis (n= 142). If the patient had one or
more contraindications, the clinician involved the PWI-DWI mis-
match ratio and mismatch volume as a secondary parameter in the
clinical decision-making. Finally, neurological assessment quanti-
fied by NIHSS score appeared to be the least influential parameter
in the regression tree.
DISCUSSION
This study reports a 93% sensitivity and 95% specificity between
automated patient triaging by COMBAT Stroke and treatment
decisions rendered by manually outlined mismatch statistics.
Patients with significant mismatch volume and ratio (TP and FP
groups) at the time of acute MRI imaging demonstrated higher
mismatch salvage compared with those who hadn’t significant
mismatch, regardless the clinical treatment decision (Figure 4).
Not surprisingly, there was a poor agreement between COM-
BAT Stroke and the actual clinical decision made (Figure 2A). This
was most notable in patients that did not receive thrombolysis. In
that group, there were only 12 cases where there was agreement
between clinical and automated decision-making (29% speci-
ficity). In contrast, in 74 cases the clinicians decided to administer
thrombolysis when COMBAT Stroke decided against (60% sensi-
tivity). This poor correlation reflects the many different variables
associated with clinical care and treatment decisions.
Importantly, our results indicate that the patients who did not
meet mismatch treatment criteria based on COMBAT Stroke and
did not receive treatment (TN) had higher rates of recanalization
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FIGURE 4 | Descriptive variables at presentation and follow-up.
Using the confusion matrix established, descriptive variables are
presented related to the mismatch (A,D) and degree of neurological
impairment (B,E). Notably, patients who did not meet radiographic
treatment criteria based on COMBAT Stroke (C) and did not receive
treatment (TN) had equal outcomes (E,F) compared to the patients
who similarly did not meet radiographic treatment criteria, yet received
thrombolysis (FN). Red line=median, box= 25th–75th percentiles,
bars image most extreme data points not considered outliers and +
depict outliers plotted individually.
Table 2 | Summary of acute decision parameters and clinical outcome
parameters forTN and FN groups.
TN FN p
Mismatch 0 mL (0, 22) 0 mL (0, 3) 0.26
Mismatch salvage 8.2 mL (1, 34) 1.5 mL (0, 7) 0.06
Acute NIHSS 6 (4.25, 13.5) 5 (3, 7.5) 0.4
∆NIHSS 3 (2, 4) 1 (−1, 3) 0.8
Contraindications 83% 23% N/A
Recanalization 15% 8% N/A
3-Months mRS 2 (1, 3.75) 1 (0, 1.5) <0.01
3-Month NIHSS 2 (0.25, 6.5) 0 (0, 1) <0.01
(15%), larger reduction in NIHSS score (median= 3), and greater
mismatch salvage (median= 8.2 mL) compared to the patients
who similarly did not meet mismatch treatment criteria, yet
received thrombolysis (FN). The analysis of 3 months mRS and
NIHSS score outcomes revealed that patients in FN group had
significantly better functional recovery compared to TN group
(Table 2). It should be emphasized that the patients in FN group
had, in general, the mildest grade of neurological deficit at admis-
sion, Figure 4B. Therefore, selection bias may be a confounding
factor in the good functional recovery observed in this group.
Overall, this data supports a need for greater emphasis on the con-
tribution of strict radiographic criteria in the decision-making
process. Use of an automated software system such as COMBAT
Stroke may provide rapid and accurate information to objectively
contribute to the clinical decision.
In general, the patients COMBAT Stroke identified for potential
treatment and were treated had significantly better neurological
improvement,mismatch salvage,and higher rates of recanalization
compared to the other groups. This indicates the importance of the
size of the mismatch and the ratio of the potentially salvageable
and infarcted tissue with outcome following thrombolysis (18).
Our data suggests that the volumetric assessment of the mismatch
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FIGURE 5 | Decision tree analysis. The CART tree illustrates the classification of patients (PT) into thrombolysis or supportive treatment. The boxes with red
borders indicate a binary question related to the acute clinical or imaging markers. The boxes without red boarders denote patient classification into a treatment
group.
provided by COMBAT Stroke, in conjunction with the clinical
assessment, is potentially a decision-support tool for rapid and
standardized stroke management.
To further investigate the factors that influence decision to per-
form thrombolysis, a CART analysis was performed. About 93%
of patients without contraindications were administered throm-
bolysis (Figure 5). Among the treated patients, 15 and 12% of TP
and FN groups had contraindication to treatment, in contrast to
the 83 and 78% in the TN and FP groups. It could be suggested
that the clinicians in our cohort followed an “aggressive” treat-
ment strategy by administering thrombolysis in the presence of
generally accepted contraindications (19, 20). This is not entirely
unexpected, as each patient’s care must be individualized, and a
risk-benefit ratio of treatment cannot be accurately predicted or
captured from our database variables alone (21).
The main limitations of this study are those inherent in any
retrospective design. We attempted to overcome selection bias by
utilizing a consecutive cohort of ischemic stroke patients from
two detailed multi-center databases. Variations in clinical prac-
tices between, and even within, different hospitals are not pos-
sible to account for and can influence the rates of intervention
and clinical outcome (22, 23). Furthermore, individual aspects of
patient care such as the patient’s own preexisting wishes regarding
treatment are not typically captured in a retrospective analysis.
Unfortunately, the balance between actively and supportively
treated patients was highly skewed, thus drawing conclusions by
comparing the different groups should be done cautiously. The
main technical limitations in this study are the numerous auto-
matic post-processing steps in COMBAT Stroke algorithm. For
instance, the co-registration is fully automated and in cases where
the co-registration is not optimal, the determination of mismatch
volume and mismatch salvage is incorrect. To avoid incorrect esti-
mation of the radiographic parameters, we manually checked all
automated steps in the COMBAT Stroke algorithm.
Our study identifies many aspects of investigating an automated
clinical decision-support tool that can be further investigated in a
prospective fashion. These include any causal effect on neurolog-
ical outcome, radiographic outcome, and even “door-to-needle”
time. The automated process of mismatch volumetric calculation
may also prove valuable in the growing population of patients that
are treated beyond the typical treatment time window based on
dynamic imaging characteristics (24–28).
CONCLUSION
COMBAT Stroke may help to not only identify patients that are
potential candidates for thrombolysis, but also to exclude patients
that are unlikely to experience benefit. COMBAT Stroke, in addi-
tion to clinical assessment, may provide a decision-support tool
for a fast, efficient, and standardized clinical decision-making in
acute ischemic stroke.
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